Biogenvs.Moderna
BIIB vs MRNA · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Moderna is about 2.5× larger than Biogen by market cap; year to date, Moderna leads (+566.3% vs +26.2%).
Side by side
| BIIB | MRNA | |
|---|---|---|
| Market cap | $32.1B | $78.6B |
| Price | $218.43 | $197.00 |
| Today | −1.7% | +0.3% |
| Return YTD | +26.2% | +566.3% |
| Return 1Y | +45.9% | +618.7% |
| Since June 26, 2026 | +1.1% | +192.8% |
| P/E | 38.4 | — |
| P/S | 3.2 | 35.3 |
| P/B | 1.7 | 11.6 |
Data as of 2026-10-08 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
BiogenBIIB
Neurological disease is the whole focus, from multiple sclerosis to Alzheimer's, where Leqembi is partnered with Eisai.
Full BIIB profile →ModernaMRNA
Built on mRNA, the technology behind its covid vaccine. The pipeline pushes the same platform into further vaccines and into oncology.
Full MRNA profile →More BIIB & MRNA comparisons
Other head-to-heads in the Biotech & innovation segment.